Definium Therapeutics, Inc. (DFTX)

Definium Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for brain health disorders. The company was formerly known as Mind Medicine, or MindMed, and adopted the Definium name in January 2026. It is headquartered in New York City.

Its lead candidate, DT120, is a pharmaceutically optimized form of lysergide, the compound commonly known as LSD, being studied in late-stage Phase 3 trials for generalized anxiety disorder and major depressive disorder. The program is designed around a single supervised dose in a clinical setting.

Its second candidate, DT402, is the R-enantiomer of MDMA and is being studied in Phase 2a trials for core symptoms of autism spectrum disorder. The company's approach is to develop psychedelic and related compounds through the standard regulatory pathway as approved prescription medicines.